Eli Lilly Nears Deal to Buy Psychedelic Drugmaker AtaiBeckley at a Premium
LLY sits 86% above its 52-week low of $623.78.
Summary
Eli Lilly is reportedly close to acquiring AtaiBeckley, a psychedelic drugmaker, at a premium. The deal could be announced as early as this week, per Bloomberg sources. AtaiBeckley shares surged 50% premarket on the news, while Lilly's stock edged up 0.1%. This move would expand Lilly's pipeline into psychedelic therapies for mental health, an area gaining regulatory momentum after Trump's April directive to accelerate FDA reviews. The acquisition aligns with Lilly's aggressive dealmaking, following its $1.1B purchase and $2.3B buyback announced in Q1. No financial terms were disclosed, but the premium suggests strong strategic interest. Watch for an official announcement and deal terms this week.
At the time of this announcement, LLY was trading at $1,158.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.